Navigation Links
The MDS Foundation supports the FDA's decision to expand vidaza label to include survival data
Date:8/25/2008

Crosswicks, NJ (August 22, 2008) The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Administration (FDA) to extend the label for VIDAZA (azacitidine) to include data from the AZA-001 clinical trial. Results from the trial found that azacitidine is the only agent which has been shown to extend survival in MDS patients.

Data from the AZA-001 trial was recently presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting and found that azacitidine nearly doubled the two-year survival rate for higher-risk MDS patients compared to conventional care regimens (CCR) with a mean survival of 24.5 months compared to 15 months for patients who received CCR.

"We are extremely encouraged by the results of the AZA-001 trial which for the first time showed that survival could be extended for patients with higher-risk MDS," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "Roughly 30 percent of patients diagnosed with MDS will progress to acute myeloid leukemia (AML), but treatment with VIDAZA significantly delays this progression. VIDAZA not only has great survival data in MDS, but can also prevent progression to AML."

Results from the trial also showed that azacitidine reduced the need for blood transfusions in higher-risk MDS patients with nearly half (45 percent) of patients who were transfusion dependent at the start of the trial achieving transfusion independence.

Additionally, azacitidine was shown to delay the progression of MDS to acute myeloid leukemia (AML). Roughly 30 percent of patient diagnosed with MDS will progress to AML. The delay in progression is especially significant because patients with MDS are typically over the age of 65. According to the National Institute of Health, in this patient group, the average 5-year survival rate after diagnosis with AML is only approximately four percent.

MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the function of blood cells, either red blood cells, white blood cells or platelets. The incidence of MDS is underestimated.


'/>"/>

Contact: Kathy Heptinstall
800-637-0839
Weber Shandwick Worldwide
Source:Eurekalert

Related biology news :

1. New York Stem Cell Foundation announces third annual Translational Stem Cell Research Conference
2. Michael J. Fox Foundation PD Therapeutics Conference
3. Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinsons Disease
4. W.M. Keck Foundation grant funds reproductive science research
5. W.M. Keck Foundation announces 2008 class of Distinguished Young Scholars in Medical Research
6. Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinsons
7. Glenn Foundation for Medical Research commits $5 million to study aging
8. BBVA Foundation Awards for Biodiversity Conservation
9. The Parkinsons Disease Foundation awards $950,000 in seed grants
10. The AGA Foundation invests in gastroenterologys future
11. European Science Foundation aims to strengthen regenerative medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
(Date:3/16/2017)... 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... Used combined in one project, multi-biometric ... ...
(Date:3/9/2017)... SAN FRANCISCO and MOUNTAIN VIEW, ... Zipongo , "Eating Well Made Simple," and 23andMe ... to help guide better food choices.  Zipongo can now ... only their food preferences, health goals and biometrics, but ... to certain food choices. Zipongo,s personalized food ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major ... and GSK to generate genetic sequence data from the 500,000 ... enable researchers to gain valuable insights to support advances in ... serious and life threatening diseases. ... Genetic evidence has revolutionized scientific ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
Breaking Biology Technology: